ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic sclerosis"

  • Abstract Number: 1568 • ACR Convergence 2025

    A Novel Endothelial Cell Profiling Assay to Identify Systemic Sclerosis Patient Characteristics at the Endothelial Cell Level

    Eva Hoekstra1, Rudmer Postma1, Nils Steinz2, Wieke van Oostveen1, Roel Bijkerk1, Vincent van Duinen2, Rachel Knevel2, Tom Huizinga2, Anton jan van Zonneveld1, Jeska de Vries-Bouwstra2 and Cynthia Fehres1, 1Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Vasculopathy, a hallmark clinical feature in systemic sclerosis (SSc), is a consequence of endothelial cell (EC) damage and dysfunction and might precede tissue fibrosis.…
  • Abstract Number: 1015 • ACR Convergence 2025

    Refining Administrative Algorithms For Accurate Identification of Patients with Systemic Sclerosis In Trinetx Research Network

    Gulsen Ozen1, Michael O'Rorke2, Paul Romitti2 and Robyn Domsic3, 1University of Iowa, Carver College of Medicine, Division of Immunology, Coralville, IA, 2University of Iowa College of Public Health, Department of Epidemiology, Iowa City, IA, 3University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Large data-driven medical research is invaluable in answering questions about epidemiology, genetics, therapeutics, and outcomes of rare diseases. Systemic sclerosis (SSc) is rare yet…
  • Abstract Number: 0957 • ACR Convergence 2025

    Multi-Omic Profiling Reveals a Monocyte-Vascular Signature Associated with the Regression of Skin Fibrosis in SSc

    Astrid Hofman1, Pietro Bearzi2, Elena Pachera3, Cosimo Bruni4, Lumeng Li2, Laura Much5, Kristina Bürki1, Mike Becker6, Anna-Maria Hoffmann-Vold7 and Oliver Distler8, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, 2Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, 3University Hospital Zurich, Zurich, Switzerland, 4University of Zurich, Zurich, Switzerland, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 6Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, 7Oslo University Hospital, Oslo, Norway, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: Regression of skin fibrosis is a feature of the natural history of dcSSc. The molecular mechanisms underlying this resolution remain unclear. This study aims…
  • Abstract Number: 0685 • ACR Convergence 2025

    Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention

    Areeka Memon1, Monique Hinchcliff2 and Amir Masoud3, 1Yale New Haven Health, New Haven, CT, 2Yale School of Medicine, Westport, CT, 3Hartford Healthcare, hartford

    Background/Purpose: Gastrointestinal tract (GIT) symptoms impact up to 90% of individuals with SSc. Hiatal hernia, decreased esophageal contractility, and lower esophageal sphincter tone contribute to…
  • Abstract Number: 0881 • ACR Convergence 2025

    Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease

    Shu-Ju Lin1, Kimberly Taylor2, Shen Yang3, Qinwei Chen4, Shehani Alexander1, Ye Cao5, Takanori Sasaki5, Deepak Rao5, Nunzio Bottini6, Francesco Boin3 and Richard Ainsworth4, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2UC San Francisco, San Francisco, CA, 3Cedars-Sinai Medical Center, Beverly Hills, CA, 4Cedars Sinai Medical Center, Los Angeles, CA, 5Brigham and Women's Hospital, Boston, MA, 6Cedars Sinai Medical Center, Beverly Hills, CA

    Background/Purpose: Circulating monocytes with pro-inflammatory and pro-fibrotic phenotype have been implicated in SSc-ILD pathogenesis, but their potential trajectory to mature cell lineage macrophages driving organ-specific…
  • Abstract Number: 2494 • ACR Convergence 2025

    Abatacept Reduces CD319+ (SLAM-F7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis

    Mikel Gurrea-Rubio1, Kohei Maeda2, Qi Wu3, Phillip L Campbell2, Camila I Amarista2, Alexander Stinson4, Ray Ohara5, Laura Cooney6, Michael Whitfield7, Pei-Suen Tsou8, Dinesh Khanna8 and David Fox9, 1University of Michigan - Ann Arbor, Ann Arbor, MI, 2Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, 3Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, 4University of Michigan, Department of Internal Medicine, Division of Rheumatology, Ann Arbor, MI, 5University of Michigan, Department of Internal Medicine, Division of Rheumatology, West Bloomfield, MI, 6Immune Tolerance Network, Ann Arbor, MI, 7Geisel School of Medicine, Lebanon, NH, 8University of Michigan, Ann Arbor, MI, 9University of Michigan, Dexter, MI

    Background/Purpose: While the ASSET clinical trial (placebo-controlled blinded trial of abatacept) in patients with diffuse cutaneous systemic sclerosis (dcSSc) did not meet its primary endpoint…
  • Abstract Number: 2470 • ACR Convergence 2025

    Impaired Myocardial Flow Reserve on 82-Rubidium Positron Emission Tomography in Patients with Systemic Sclerosis

    Attila Feher1, Morgan Emokpae2, Bindu Koyi2, Ibolya Csecs2, Baran Gunes3, Albert Sinusas2 and Monique Hinchcliff4, 1Yale University School of Medicine - New Haven, CT, New Haven, CT, 2Yale School of Medicine, New Haven, 3Yale University School of Medicine, Pompton Plains, NJ, 4Yale School of Medicine, Westport, CT

    Background/Purpose: Cardiovascular death ranks as the second leading cause of mortality related to systemic sclerosis (SSc), with coronary microvascular dysfunction (CMVD) likely contributing to this…
  • Abstract Number: 1833 • ACR Convergence 2025

    DM618: A Novel Anti-IL12p35 Antibody Specifically Inhibiting IL-12 with Therapeutic Potential in a Set of Autoimmune Diseases

    Dong ZHANG, Guangan Hu, Xiaodong Jiang, Quanju Zhao, Tainfei Hou, Zhengwang Sun, Mousheng Xu and Nan Bing, D2M Biotherapeutic, Inc, NATICK, MA

    Background/Purpose: IL-12, via its p35 subunit, drives Th1-mediated pathology in autoimmune diseases. Genome-wide association studies (GWAS) suggested that IL12A encoding IL12p35 is associated with systemic…
  • Abstract Number: 1569 • ACR Convergence 2025

    Can We Use Patient Reported Outcomes For Home-monitoring in SSc?

    Eva Hoekstra1, Katherine van der Wouden2, Queeny Madari1, Saad Ahmed3, Lianne Kwant1, Ada Hortensius-Varkevisser1, Emiel Marges1, Jacopo Ciaffi4, Anne Schouffoer5, Tom Huizinga6 and Jeska de Vries-Bouwstra6, 1Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, 2Leiden University Medical Center and Amsterdam University Medical Center, Leiden, Zuid-Holland, Netherlands, 3LUMC, Leiden, Netherlands, 4IRCCS Istituto Ortopedico Rizzoli, Bologna, Bologna, Italy, 5HagaZiekenhuis the Hague, the Hague, Netherlands, 6Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Home-monitoring is a suitable strategy to reduce the frequency of hospital visits, and alleviate strain on healthcare resources. However, in systemic sclerosis (SSc) this…
  • Abstract Number: 0997 • ACR Convergence 2025

    Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 

    Olivia Pryor1, Catalina Burbano2, Nathaniel Bagge2, Rutuja Kulkarni2, Heather F. Jones2, Livio Dukaj2, Shoshana M.K. Bloom2, Jackson Lirette2, Rachel Lent2, Prachi Dhanania2, Nicole A. Ladd2, Ryan Kritzer2, Hana Husic2, Shobitha Jillella2, Candace R. Perullo2, Jinyu Zhu2, Teagan J. Parsons2, Ira Jain2, Rakshika Balasubramaniyam2, Kenneth L. Jahan2, Vivin Karthik2, Alexander Cristofaro1, Chandan K. Pavuluri2, Jenna LaBelle2, Laurie Barefoot2, Shrikanta Chattopadhyay2, Kim M. Cirelli2, Mollie M. Jurewicz2, Andrew P. Ferretti2 and Cagan Gurer2, 1TScan Therapeutics, Waltham, 2TScan Therapeutics, Waltham, MA

    Background/Purpose: Selective modulation of autoimmune responses through antigen-specific therapies represents a promising direction for improving treatment specificity and safety. Genetic associations with HLA class II…
  • Abstract Number: 0956 • ACR Convergence 2025

    Mapping Metabolic Changes in Skin Fibrosis in Systemic Sclerosis by Spatial Proteomics

    Veda Devakumar1, Yi-Nan Li2, Tim Filla3, Aleix Rius Rigau4, Andrea-Hermina Györfi5, Bilgesu Safak Tümerdem6, Ranjana Neelagar7, Minrui Liang8, Christina Bergmann9, Georg Schett10, Jörg Distler11 and Alexandru-Emil Matei12, 1Heinrich Heine University, University Clinic Düsseldorf, Düsseödorf, 2University Hospital of Düsseldorf, Düsseldorf, Germany, 3Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 4Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, 6Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 7Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Düsseldorf, Nordrhein-Westfalen, Germany, 8Huashan Hospital, Fudan University, Shanghai, China (People's Republic), 9Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 10Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 11University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 12Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany

    Background/Purpose: Several tissue resident populations undergo metabolic reprogramming during tissue fibrosis as a phenotypic adaptation to their changing metabolic demands. However, these shifts in metabolic…
  • Abstract Number: 0684 • ACR Convergence 2025

    Translation to Spanish and Linguistic Validation of the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP)

    Antonia Valenzuela1, Adriana Miguel Alvarez2, Patricia E. Carreira3, Alejandra Babini4, Diana Rocío Gil Calderón5, John Pauling6 and Tatiana Rodriguez-Reyna2, 1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Hospital Italiano, Córdoba, Argentina, 5Hospital Universitario Mayor MEDERI, Universidad del Rosario, Artmedica SAS, Bogotá, Colombia, 6North Bristol NHS Trust, Bristol, United Kingdom

    Background/Purpose: Systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP) significantly impacts patients’ quality of life, yet validated tools to assess this condition in Spanish-speaking populations are lacking. The…
  • Abstract Number: 0848 • ACR Convergence 2025

    Spatial Frequency Domain Imaging (SFDI) for Skin Assessment in Systemic Sclerosis: Insights from Histology and Clinical Correlates

    Hung Vo1, Aarohi Mehendale2, Martin Azzam3, Fatima-Ezzahrae El Adili4, Rutvi Patel3, Marcin TROJANOWSKI3, Michael York5, Eugene Kissin6, Jeffrey Browning7, Jag Bhawan3, Darren Roblyer5 and Andreea Bujor5, 1Boston Medical Center, Peabody, MA, 2Department of Biomedical Engineering, Boston University, Boston, MA, 3Boston University School of Medicine, Boston, MA, 4Boston University School of Medicine, Revere, MA, 5Boston University, Boston, MA, 6Boston University, Newton, MA, 7Boston University School of Medicine, Cambridge, MA

    Background/Purpose: Assessing skin involvement in systemic sclerosis (SSc) is complex, with no single method capturing all pathological changes. The modified Rodnan Skin Score (mRSS) is…
  • Abstract Number: 2493 • ACR Convergence 2025

    Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs

    Michael Hughes1, Graham Dinsdale2, Aayushi Agnihotri3, Joanne Manning2, Muditha Samaranayaka4, Jonathan Harris2 and Ariane Herrick5, 1The University of Manchester, Manchester, England, United Kingdom, 2Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, 3The University of Manchester, Manchester, United Kingdom, 4Salford Royal Hospital, Salford, United Kingdom, 5The University of Manchester, UK, Aberdeen, United Kingdom

    Background/Purpose: Acro-osteolysis (A-O, terminal tuft digit resorption) is characteristic of systemic sclerosis (SSc), occurring in 20-25% of patients (1). Outcome measures are much needed. Following…
  • Abstract Number: 2398 • ACR Convergence 2025

    Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England

    Jason Sillitoe1, Ewa Fiorentino-Rozek2, Gerber Gomez3, Christian Fischer3 and Caroline Wilson1, 1North East Innovation Lab, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, 2Clinical Affairs, AliveDx Suisse SA, Eysins, Vaud, Switzerland, 3Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland

    Background/Purpose: Indirect immunofluorescence assay (IFA) on HEp-2 cells (HEp-2 IFA) remains a key tool in the diagnostic work-up of autoimmune connective tissue diseases (CTD). Traditionally…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 56
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology